So Yeon Kim, MD
Assistant ProfessorCards
About
Research
Publications
2026
Disentangling KEAP1 and STK11 in KRAS-mutant (KRASm) non–small cell lung cancer (NSCLC) treated with immunotherapy.
Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Disentangling KEAP1 and STK11 in KRAS-mutant (KRASm) non–small cell lung cancer (NSCLC) treated with immunotherapy. Journal Of Clinical Oncology 2026, 44: e20583-e20583. DOI: 10.1200/jco.2026.44.16_suppl.e20583.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsCD8 T-cell densityNon-small cell lung cancerT-cell densityKS tumorsWT tumorsKRAS-mutantPatients treated with immune checkpoint inhibitorsPoor response to immune checkpoint inhibitorsResponse to immune checkpoint inhibitorsImmune checkpoint inhibitor resistanceAnti-PD-1 monotherapyAnti-PD-1Treated with immunotherapyT cell infiltrationCell lung cancerClinico-genomic databaseCD8 infiltrationCheckpoint inhibitorsChemo-ImmunotherapyPD-L1Tumor compartmentsPrognostic effectImmune-phenotypeT cellsMachine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC).
Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Le X, Luo J, Wu J, Gibbons D, Heymach J, Skoulidis F, Kim S, Schoenfeld A, Awad M, Zhang J, Vokes N. Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2026, 44: e20609-e20609. DOI: 10.1200/jco.2026.44.16_suppl.e20609.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsNon-squamous NSCLCBiomarkers of response to immunotherapyAssociated with worse outcomesProgression-free survivalResponse to immunotherapyPD-L1KRAS mutant NSCLCAssociated with resistance to immune checkpoint inhibitorsWorse outcomesResistance to immune checkpoint inhibitorsTreated with immune checkpoint inhibitorsAnti-PD-1 monotherapyAnti-CTLA-4 therapyTreatment selectionTumor mutational burdenTreatment intensification strategiesClinico-genomic databasePredictive of responseImmunotherapy selectionKRASwt patientsCheckpoint inhibitorsChemo-ImmunotherapyLiver metastasesKRAS wildtypePan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study
Murciano-Goroff Y, Hollebecque A, Heist R, Cassier P, Han J, Kim S, Sabari J, Tosi D, Sacher A, Burns T, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor J, Nagasaka M, You A, McNeely S, Peter R, Fink A, Chen A, Oxnard G, Willard M, Kuboki Y, Koyama T. Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study. Nature Communications 2026, 17: 3834. PMID: 41820335, PMCID: PMC13121619, DOI: 10.1038/s41467-026-69943-7.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityKRAS G12C inhibitorsAdvanced solid tumorsKRAS G12C mutantG12C inhibitorsSolid tumorsFirst-in-human phase 1 studyInvestigation of combination therapyFirst-in-human studyAntitumor activityGrade 3 TRAEsPhase 2 dosePhase 1 studyPhase 1a dose escalationDose expansionDose escalationBrain metastasesCombination therapyTumor typesAdverse eventsIntracranial responseNo gradeKRASGrade 1PatientsClinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials
Gong G, Liu J, Pandya S, Taborda C, Wiesendanger N, Price N, Byron W, Coppi A, Young P, Wiess C, Dunning H, Barganier C, Brodeur R, Fischbach N, LoRusso P, Pusztai L, Kim S, Rozenblit M, Cecchini M, Mongiu A, Mendez L, Kaftan E, Torre C, Krumholz H, Krop I, Schulz W, Lustberg M, Kunz P. Clinical Trial Patient Matching: A Real-Time, Common Data Model and Artificial Intelligence–Driven System for Semiautomated Patient Prescreening in Cancer Clinical Trials. JCO Clinical Cancer Informatics 2026, 10: e2500262. PMID: 41512229, DOI: 10.1200/cci-25-00262.Peer-Reviewed Original ResearchConceptsObservational Medical Outcomes PartnershipHealth systemColorectal cancerElectronic health record dataCancer clinical trial enrollmentChart reviewHealth record dataManual chart reviewClinical trial recruitmentClinical trialsCancer clinical trialsCancer specialtiesCommon data modelScreen timeColorectal cancer trialsClinical trial enrollmentTrial recruitmentClinical chart reviewConsent ratesPatient accessExhaustive chart reviewMetastatic colorectal cancerEnrollment challengesRecord dataTrial enrollment
2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity
Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato D, Naidoo J, Loza M, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Montrone M, Owen D, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis D, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity. Lung Cancer 2025, 209: 108799. PMID: 41108882, DOI: 10.1016/j.lungcan.2025.108799.Peer-Reviewed Original ResearchConceptsAdvanced NSCLCLong-term outcomesOverall survivalPembrolizumab monotherapyPD-L1Performance statusUnivariate analysisClinical trialsPredictors of 5-year survivalLong-term benefitsPredictors of early mortalityPrediction of 5-year survivalSurvival ratePD-L1 TPSSingle agent immunotherapyCharacteristics associated with survivalPD-L1 expressionLong-term outcome predictionPoor performance statusBaseline corticosteroid useYear Follow-UpLong-term survivalLong-term survivorsMedian survivalBone metastasesTransformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato D, La Cava G, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Alessi J, Montrone M, Owen D, Ramella S, Signorelli D, Fidler M, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D’Alessio A, Banna G, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B, Soda P, Caruso C, Guarrasi V. Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e012423. PMID: 41022528, PMCID: PMC12481261, DOI: 10.1136/jitc-2025-012423.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerArea under the curveLong-term outcomesRisk of deathPD-L1Eastern Cooperative Oncology Group performance statusNon-cancer-related factorsLong-term follow-upImpact of smoking statusFirst-line pembrolizumabCell lung cancerProtective rolePrimary risk factorMetastatic burdenPerformance statusCancer prognosticationEarly mortalityLung cancerC-indexFollow-upGlobal RegistryPrognostic trendPembrolizumabBaseline variablesLasering in on Uncommon EGFR Mutations
Kim S, Politi K, Goldberg S. Lasering in on Uncommon EGFR Mutations. Journal Of Thoracic Oncology 2025, 20: 1148-1151. PMID: 40914593, DOI: 10.1016/j.jtho.2025.06.014.Commentaries, Editorials and LettersKRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape
Frisch A, Martin E, Kim S, Riess J, Sen T, Karim N. KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape. The Oncologist 2025, 30: oyaf153. PMID: 40586765, PMCID: PMC12207871, DOI: 10.1093/oncolo/oyaf153.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerKirsten rat sarcoma virusOncogenic driver genesCell lung cancerEra of precision medicineInhibitor monotherapyRat sarcoma virusTargeted therapyNon-smallNSCLC treatmentLung cancerClinical trialsInhibitor treatmentDriver genesImmunotherapyPrecision medicineTherapyTreatmentSarcoma virusMonotherapyMalignancyMolecular biologyGenesCancerEvolving LandscapeSmall Cell Lung Cancer
Kim S, Park H, Chiang A. Small Cell Lung Cancer. JAMA: The Journal Of The American Medical Association 2025, 333: 1906-1917. PMID: 40163214, DOI: 10.1001/jama.2025.0560.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThis study investigates the treatment advancements for small cell lung cancer, showing that combining chemotherapy, radiotherapy, and immunotherapy improves survival rates, highlighting the importance of early diagnosis and tailored therapy.Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]
Ayoade O, Canavan M, Zolfaghari E, Caturegli G, Kim S, Boffa D. Erratum to ‘Recent Survival Gains in Stage IV NSCLC by Sociodemographic Strata’ [JTO Clinical and Research Reports Volume 6 Issue 4 (2025) 100798]. JTO Clinical And Research Reports 2025, 6: 100850. PMID: 41473839, PMCID: PMC12745935, DOI: 10.1016/j.jtocrr.2025.100850.Commentaries, Editorials and Letters
Academic Achievements & Community Involvement
Clinical Care
Overview
So Yeon Kim, MD, is a medical oncologist who cares for patients with lung cancer, an area that she says is changing rapidly, thanks to new drugs in the past decade, targeted treatments, and immunotherapies that have led to significant improvements in outcomes even in people with advanced forms of the disease.
“I always knew I wanted to do something to help people,” Dr. Kim says. “I ultimately chose oncology because I enjoyed the long-term relationships I was able to build with patients and families. I really enjoy working with cancer patients because they are among the most resilient and courageous people, who continue to fight against a disease that still has many more problems to solve.”
Dr. Kim is working with colleagues toward personalizing cancer treatment for all patients with carefully selected treatment options based on the tumor’s “molecular fingerprint,” she says. “At Yale, there is a lot of ongoing scientific collaboration between clinicians and researchers that is helping bring the latest scientific discoveries to patients with the goal of improving their outcomes.”
An assistant professor at Yale School of Medicine, Dr. Kim focuses her research on both targeted treatment options and immunotherapy. “Oncology is a humbling field that can bring up more questions than answers, but I think that ultimately allows space for creativity and innovation,” she says. “While my research interests currently remain broad, I am interested in developing a more personalized approach to lung cancer care as we learn more about the science around what drives specific patients to respond better to certain therapies than to others,” she says.
Clinical Specialties
Fact Sheets
Lung Cancer
Learn More on Yale MedicineLung Cancer in Nonsmokers
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale MedicineNon-Small Cell Lung Cancer
Learn More on Yale Medicine
Yale Medicine News
News
News
- June 02, 2026
Yale Cancer Center Researchers and Trainees Present at 2026 ASCO Annual Meeting
- May 15, 2026
Yale Cancer Center Researchers Highlight Breakthroughs Across Cancer Care at ASCO 2026
- July 07, 2025
International Exchange Fosters Clinical and Research Collaboration
- June 06, 2025
Yale Cancer Center Researchers and Trainees Present at 2025 ASCO Annual Meeting
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.